SCHEMBL21134827

SCHEMBL21134827

O=C(OC1C2CCC(O2)C(OC(=O)c2ccccc2)C1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LGALS9 O00182 1/20 0.46
LGALS1 P09382 1/20 0.46
LGALS3 P17931 1/20 0.46
LGALS7; LGALS7B P47929 1/20 0.46
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
PTPN1 P18031 1/20 0.45
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
F2 P00734 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27052488 0.84 APOBEC3A (0.43) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL7154462 0.83 LMNA (0.61) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL21768324 0.83 LMNA (0.61) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL7154464 0.83 LMNA (0.61) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL27052372 0.83 MEN1 (0.44) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL27052452 0.83 CHRNA7 (0.46) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL27052365 0.82 CHRM2 (0.49) CHRNA7HTR3EHTR3BHTR3AHTR3D
SCHEMBL27052630 0.81 MEN1 (0.43) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL19889869 0.80 BCHE (0.43) CHRNA7MEN1KMT2ALGALS9LGALS1
SCHEMBL19889884 0.80 BCHE (0.43) CHRNA7MEN1KMT2ALGALS9LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829509-B2 Pure heptasulfated disaccharides having improved oral bioavailability OPKO PHARMACEUTICALS, LLC (US) 2020-11-10 US disclosed
US-20190185503-A1 PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY OPKO PHARMACEUTICALS, LLC. 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829509-B2 Pure heptasulfated disaccharides having improved oral bioavailability SI, GYS1, UGGT1 CHRNA7 2314/4885MEN1 3918/4885KMT2A 4002/4885
US-20190185503-A1 PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY SI, GYS1, UGGT1 CHRNA7 2314/4885MEN1 3918/4885KMT2A 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.